BlackRock Amends OptimizeRx Stake Filing (SC 13G/A)
Ticker: OPRX · Form: SC 13G/A · Filed: Jan 29, 2024 · CIK: 1448431
| Field | Detail |
|---|---|
| Company | Optimizerx CORP (OPRX) |
| Form Type | SC 13G/A |
| Filed Date | Jan 29, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investing
TL;DR
**BlackRock just updated its OptimizeRx ownership, signaling its current institutional stake.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 29, 2024, indicating its ownership of OptimizeRx Corp's common stock as of December 31, 2023. This filing, Amendment No. 7, updates their previous disclosures regarding their stake in the company. This matters to investors because BlackRock is a major institutional investor, and changes in their holdings can signal their confidence (or lack thereof) in OptimizeRx's future performance, potentially influencing other investors' decisions.
Why It Matters
This filing shows BlackRock's updated ownership position in OptimizeRx, providing transparency on a significant institutional investor's involvement, which can impact market perception and stock stability.
Risk Assessment
Risk Level: low — This is a routine disclosure filing by a large institutional investor and does not inherently indicate significant risk.
Analyst Insight
Investors should note BlackRock's continued presence as a holder, but this filing alone doesn't provide enough detail to warrant immediate action. Further analysis of BlackRock's specific percentage ownership (which is not detailed in this excerpt) and any changes from previous filings would be prudent.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- OptimizeRx Corp (company) — the subject company whose securities are being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 29, 2024 (date) — the filing date of the SC 13G/A
- Amendment No: 7 (number) — the specific amendment number for this filing
Forward-Looking Statements
- BlackRock will continue to be a significant institutional holder of OptimizeRx Corp common stock. (BlackRock Inc.) — high confidence, target: 2025-01-29
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, filed under the Securities Exchange Act of 1934.
Who is the reporting person in this filing?
The reporting person is BlackRock, Inc., a major institutional investment manager.
What is the subject company whose securities are being reported?
The subject company is OptimizeRx Corp, identified by the CUSIP Number 68401U204.
What was the 'Date of Event Which Requires Filing of this Statement'?
The date of the event which requires filing of this statement was December 31, 2023.
What is the CUSIP Number for the securities reported?
The CUSIP Number for the Common Stock of OptimizeRx Corp is 68401U204.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 29, 2024 regarding OptimizeRx Corp (OPRX).